NRx Pharmaceuticals, Inc. (NRXPW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO | 825k | -- | 1957 |
| Mr. Matthew Patrick Duffy | Chief Business Officer & Co-CEO of Hope Therapeutics | 338k | -- | 1963 |
| Mr. Michael S. Abrams | Chief Financial Officer | -- | -- | 1970 |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 240k | -- | 1961 |
| Suzanne Messere | Investor Relations | -- | -- | -- |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist | -- | -- | 1947 |
NRx Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available